Home > CCS1477

molecules of the month

<< Back to January

CCS1477

Recent Publication

p300/CBP bromodomain inhibitor

PD observed in serial biopsies from Ph. I

50 mg QD, 3-d-on-4-off; origin not discussed

Cancer Discovery, Jan. 11, 2021

ICR / Royal Marsden / CellCentric, UK

The CellCentric p300/CBP inhibitor, CCS1477, is an orally available drug in early development for advanced prostate cancer, and is structurally distinct from the p300/CBP inhibitor we covered in Apr.…

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

LEARN MORE

CCS1477

this content is exclusive to Premium members

this content is exclusive to
Premium members